Chief Financial Officer, Treasurer and Secretary · X4 Pharmaceuticals, Inc (XFOR)

Adam Mostafa

A named executive officer of X4 Pharmaceuticals in every fiscal year CompBrief holds from FY2018 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,307,223

Salary $510,000Stock awards $137,703Bonus $102,000

FY2023: $1,152,848

2nd of 3 named executive officers at X4 Pharmaceuticals by FY2024 total.

3 named officers on file for X4 Pharmaceuticals, FY2024

Adam Mostafa’s pay file — $29

  • 7 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how X4 Pharmaceuticals’s whole pay program stands against its peers

  • X4 Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on XFOR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2025 (DEF 14A).

Free

Get Adam Mostafa’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Adam Mostafa compensation by year

X4 Pharmaceuticals Summary Compensation Table · all 7 fiscal years held
In US dollars, as X4 Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020FY2021FY2022FY2023FY2024
Salary$109,285$372,275$400,000$430,193$458,973$486,192$510,000
Bonus$0$0$0$0$46,085$0$102,000
Stock awards$0$155,819$612,950$723,518$226,800$452,064$137,703
Option awards$480,789$168,771$0$0$954,900$0$377,381
Non-equity incentive$38,250$168,341$163,600$185,220$193,555$214,000$179,520
Pension and deferred compensation$0$0$0$0$0$0$0
All other$90$1,025$564$0$569$592$619
Total$628,414$866,231$1,177,114$1,338,931$1,880,882$1,152,848$1,307,223

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: X4 Pharmaceuticals, Inc DEF 14A filed April 25, 2025, accession 0001628280-25-019926, and prior-year filings. Open the filing on EDGAR.

How this page was built: the X4 Pharmaceuticals, Inc filed document, accession 0001628280-25-019926. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2025.

$628K
$866K
$1.2M
$1.3M
$1.9M
$1.2M
$1.3M
FY18
FY19
FY20
FY21
FY22
FY23
FY24
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
PSU149,547$109,169—
Option450,000—$1.80
Option523,414—$0.92

Per the Outstanding Equity Awards at Fiscal Year-End table in X4 Pharmaceuticals, Inc's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

X4 Pharmaceuticals’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Paula RaganPresident and Chief Executive Officer$2,145,041
Adam Mostafa · this pageChief Financial Officer, Treasurer and Secretary$1,307,223
Mark BaldryChief Commercial Officer$1,171,703

The full X4 Pharmaceuticals compensation record

free company brief

This page is one person within X4 Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are X4 Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Adam Mostafa's compensation dossier · One-time report. No refunds.